Vivimed Labs Ltd Stock Analysis

BSE: 532660 | NSE: VIVIMEDLAB | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 27-Mar-2023 18:02
6.67 0.00 (0.00%)

DeciZen - Make an Informed Decision on Vivimed Labs

M-Cap below 100cr DeciZen not available

Vivimed Labs Price Chart

P/E Ratio ( SA) :
Market Cap :
55.3 Cr.
52-wk low :
52-wk high :
Bole Toh?

1. Is Vivimed Labs Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Vivimed Labs Ltd is a average quality company.

2. Is Vivimed Labs Ltd undervalued or overvalued?

The key valuation ratios of Vivimed Labs Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

3. Is Vivimed Labs Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Vivimed Labs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Vivimed Labs:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Vivimed Labs Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 7.5%6%6.8%4.8%16.4%4.7%4.5%1.9%0.7%-4.8%-
Value Creation Index -0.5-0.6-0.5-0.70.2-0.7-0.7-0.9-1.0-1.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 423432430319570261252277210218190
YoY Gr. Rt. %-2.1%-0.4%-25.8%78.4%-54.1%-3.7%9.9%-24.1%4%-
YoY Gr. Rt. %--41.3%21%-71.1%1803.5%-90.2%-52.5%-321.3%NANA-
BVPS (₹) 42.745.84645.564.564.264.862.258.750.643
Adj Net Profit 33.219.723.86.913113.16.2-13.8-23.3-67.8-82
Cash Flow from Ops. 44.2-44.941.3-54.228.2207827518025.3-
Debt/CF from Ops. 10-14.216.9-


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -7.1%-17.5%-4.6%4%
Adj EPS -207.9%-187.2%-321.7%NA
BVPS 1.9-4.8-7.9-13.8
Share Price -19.4% -37.7% -3.6% -55.6%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity %
Op. Profit Mgn % 21.721.827.
Net Profit Mgn %
Debt to Equity
Working Cap Days 3324144967544709869027528657420
Cash Conv. Cycle 1642302974862816085684355234740

Recent Performance Summary

Debt to equity has declined versus last 3 years average to 0.85

Return on Equity is Poor

Sales growth has been subdued in last 3 years -4.64%

Sales growth is not so good in last 4 quarters at 0.84%

Latest Financials - Vivimed Labs Ltd.

Standalone Consolidated
TTM EPS (₹) -9.9 -9.8
TTM Sales (₹ Cr.) 190 211
BVPS (₹.) 43 31.8
Reserves (₹ Cr.) 340 247
P/BV 0.16 0.21
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 6.67 / 17.37
All Time Low / High (₹) 6.44 / 153.30
Market Cap (₹ Cr.) 55.3
Equity (₹ Cr.) 16.6
Face Value (₹) 2
Industry PE 36.2

Management X-Ray of Vivimed Labs :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *60.0960.0954.2054.2054.2054.2040.0237.1137.1137.11
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Vivimed Labs

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Vivimed Labs Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Vivimed Labs on 27-Mar-2023 18:02 is : 6.67.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 27-Mar-2023 18:02 the market cap of Vivimed Labs stood at ₹ 55.30.
The latest PE ratio of Vivimed Labs as of 27-Mar-2023 18:02 is 0.00.
The latest PB ratio of Vivimed Labs as of 27-Mar-2023 18:02 is 0.16
The 52-week high of Vivimed Labs is ₹ 17.37 and the 52-week low is ₹ 6.67.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Vivimed Labs is ₹ 190.2 ( Cr.) .

About Vivimed Labs Ltd

Vivimed Labs Ltd was originally incorporated as Emgi Pharmaceuticals & Chemicals Private Limited on 22-09-1988 with Registrar of Companies of Karnataka, Bangalore and subsequently converted into a public limited company on April 21, 1994. The name of the company has been changed to Vivimed Labs Limited on  April 22,1997.

The company was originally promoted by A. M. Rao. In 1989  Santosh Varalwar and  Subhash Varalwar acquired Emgi Pharmaceuticals and Chemicals Limited and commenced manufacturing of bulk drugs in 1991.

The company’s manufacturing unit is located at Bidar, Karnataka, where it was originally engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and bulk drugs like Ibuprofen etc. However, due to downward price movement in the products of the company during 1995, it gradually moved over to manufacturing specialty chemicals and cosmetic ingredients like Triclosan, Avis etc. catering to global and domestic markets.

Vivimed started production of Triclosan with a very small capacity of 5 MT p.a. in the year 1999 and increased its capacity to 225 MT p.a. over a period of next 5 years. The production capacity was further doubled by adding one more production block in March 2004.

Touching lives on another front, they are fighting microbes in home. In the kitchen, in the linen and more, their antimicrobials deliver clean living. Their high-end chemistry also coats the screen of mobile telephone and car’s photochromatic windscreen. For the photographic industry they remain a timeless answer. Their photosynthetic and photographic chemicals have been products of choice for decades now.

Product range of the company includes:

  • Triclosan  VIV 20
  • Avis (Avo benzone)
  • Calcium Glycero Phosphate (CaGP)
  • Chlorphenesin – Cosvat (Anti Fungal)
  • NDGA (Anti-oxidant)
  • Hair care
  • Oral care
  • Anti microbial
  • Skin care
  • Sun care


1988 & 1989•  Incorporated on September 22, 1988•  Death of original promoter Mr. A. M. Rao•  Acquired by Mr. Santosh Varalwar and Mr. Subhash Varalwar

1990 •  Commenced production of Non-Steroidal Anti-Inflammatory Drug (NSAID) – IBUPROFEN.

1994 •  Diversification and expansion of product mix by adding other APIs viz. Chlorzoxazone (Skeletal disorders), Nalidixic Acid (Anti-diarrheas) and Flucanazole (Anti-fungal).

1995 •  Diversification into specialty chemicals by production of Triclosan.

1996 •  R&D was commenced with facilities having an integrated instrumentation for organicsynthesis, Microbiology and pre-formulation studies.

1997 •  Process Innovation of Anti-bacterial and clearance of innovative route of synthesis for Triclosan.• Grant of patent for VIV-20 (Triclosan) by the Indian Patents Office.1998 – 99• Qualified for supply to Unilever’s Asian locations after Audit of manufacturing facility by a team of Unilever Plc.•  Triclosan customer base expanded to UK, France, Germany as well as domestic market.

2002 •  Approved by Unilever group Companies in Asian/Middle & Far East Companies for usage of Enamel Protective Agent manufactured by the company in their oral care formulations.•  Developed Anti-fungal for usage in High-end cosmetic and pre-formulation blends.•  Vivimed emerges as a second chemical company located outside USA/Europe to get the US EPA’s registration for Triclosan as 99% ingredient.•  Vivimed’s Quality Management System gets ISO 9001:2000 certification.

2003 •  Signed Confidential Sale Agreement with HLL for R&D, scaling up and commercialization of product coded as A123.•  Commencement of EMS Audit for ISO 14001 certification.

2004 •  Introduced new products for anti-dandruff and skin care application•  Triclosan production capacity increased from 225 MT p.a. to 480 MT p.a.•  Developed novel synthetic process to manufacture a premium anti-oxidant and anti-cancer molecule branded as VINTOX

2012ʉۢ Vivimed launch Nisarg Soapnut at in-cosmetics, Barcelona.

2013• Vivimed Labs Limited signed an agreement to acquire Actavis Pharma Manufacturing Pvt. Ltd.’s solid oral dosage (“SOD”) facility in Alathur, Tamil Nadu, India. The facility acquired from its parent Actavis Holding Asia B.V., an affiliate of Actavis Inc.

2014 • Vivimed received the PIC/S (Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme) GMP (Good Manufacturing Practice) approval for one of its pharmaceuticals manufacturing facilities in Jeedimetla, Hyderabad for the supply of finished dosage formulations to the CIS (Commonwealth of Independent States) region.

Achievements/ recognition:

  • ISO 9001:2000 and ISO14001
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now